Business
Result of AGM
Result of AGM.
About this update from Immupharma Plc
12 June 2025 ImmuPharma PLC ("ImmuPharma" or the "Company") 2025 RESULT OF ANNUAL GENERAL MEETING ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that five of the six resolutions (Resolutions 1 - 5 inclusive) were duly passed by shareholders, while the special resolution (which required approval of 75% of votes cast to pass), was not approved. Details are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year ended 31 December 2024 together with the reports thereon of the directors and auditors of the Company 88,682,323 74 30,840,722 26 74,472 2. To re-appoint Dr Tim Franklin as a director of the Company 86,938,536 74 31,136,460 26 1,522,521 3. To re-appoint Tim McCarthy as a director of the Company 86,900,286 73 32,579,135 27 118,096 4. To re-appoint Crowe UK LLP as Auditor of the Company 86,901,988 76 27,981,718 24 4,713,811 5. That the directors be authorised for the purpose of Section 551 of the Companies Act 2006 (the "Act") to allot shares on the basis as set out in the Notice of Meeting 84,856,858 71 34,558,813 29 181,846 SPECIAL RESOLUTION 6. That, subject to the passing of Resolution 5 the directors be and they are hereby empowered pursuant to section 571 of the Act to allot equity securities as set out in the Notice of Meeting 84,812,828 71 34,602,843 29 181,846 As at the date of the AGM, the number of issued ordinary shares of the Company was 499,723,932 shares, which was the total number of shares entitling the holders to attend and vote for or against all resolutions. In accordance with the Company's Articles of Association, every member has one vote for every share held. Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution. Proxy appointments which gave discretion to the Chairman have been included in the "for" total. Ends For further information please contact: ImmuPharma PLC ( www.immupharma.com ) Tim McCarthy, Chief Executive Officer and Chairman Lisa Baderoon, Head of Investor Relations +44 (0) 207 206 2650 + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge, Bob Pountney SI Capital (Joint Broker) Nick Emerson +44 (0) 203 36 8 3550 +44 (0) 203 650 3650/51 +44 (0) 1483 413500 Notes to Editors About ImmuPharma PLC ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases. For additional information about ImmuPharma please visit www.immupharma.co.uk ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.